Scoopfeeds — Intelligent news, curated.
Stifel reiterates Summit Therapeutics stock rating on trial data
business

Stifel reiterates Summit Therapeutics stock rating on trial data

Investing.com · Jun 1, 2026, 12:30 PM

Stifel reiterates Summit Therapeutics stock rating on trial data

Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop